Concourse Financial Group Securities, Inc. Summit Therapeutics Inc. Transaction History

Concourse Financial Group Securities, Inc.

$0
Q1 2025

Number of Shares

Previous 0 NaN%

Holding current value

Previous $0 NaN%

% of portfolio

100.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share
Q1 2025 May 14, 2025	BUY	$16.65 - $23.76 $0 - $0
Q4 2024 Feb 13, 2025	BUY	$17.52 - $23.46 $0 - $0
Q3 2024 Oct 10, 2024	BUY	$6.89 - $31.93 $0 - $0
Q2 2024 Jul 23, 2024	BUY	$2.39 - $10.92 $0 - $0
Q1 2024 Apr 30, 2024	BUY	$2.55 - $5.07 $0 - $0
Q4 2023 Feb 07, 2024	BUY	$1.67 - $2.83 $0 - $0
Q3 2023 Oct 30, 2023	BUY	$1.54 - $2.42 $0 - $0
Q3 2023 Oct 25, 2023	BUY	$1.54 - $2.42 $0 - $0
Q2 2023 Aug 10, 2023	BUY	$1.32 - $2.81 $0 - $0
Q1 2023 May 15, 2023	BUY	$1.38 - $5.41 $0 - $0
Q4 2022 Jan 30, 2023	BUY	$0.68 - $5.31 $0 - $0
Q3 2022 Nov 15, 2022	BUY	$0.89 - $1.63 $0 - $0
Q2 2022 Aug 09, 2022	BUY	$0.92 - $2.38 $0 - $0
Q1 2022 May 09, 2022	BUY	$2.0 - $3.45 $0 - $0
Q4 2021 Feb 07, 2022	BUY	$2.45 - $5.64 $0 - $0
Q3 2021 Nov 09, 2021	BUY	$4.83 - $8.27 $0 - $0
Q2 2021 Aug 13, 2021	BUY	$5.15 - $8.46 $0 - $0
Q1 2021 May 13, 2021	BUY	$5.17 - $11.19 $0 - $0
Q4 2020 Feb 02, 2021	BUY	$3.25 - $6.0 $0 - $0
Q3 2020 Nov 13, 2020	BUY	$3.08 - $3.8 $0 - $0

Others Institutions Holding SMMT

# of Institutions

236

Shares Held

86.8M

Call Options Held

1.84M

Put Options Held

3.13M

Baker Bros. Advisors LP New York, NY

24.4M
Shares

$481 Million
5.62% of portfolio
Vanguard Group Inc Valley Forge, PA

11.6M
Shares

$229 Million
0.0% of portfolio
Black Rock Inc. New York, NY

7.9M
Shares

$156 Million
0.0% of portfolio
Price T Rowe Associates Inc Baltimore, MD

6.56M
Shares

$129 Million
0.02% of portfolio
State Street Corp Boston, MA

4.85M
Shares

$95.6 Million
0.0% of portfolio

View Full List

About Summit Therapeutics Inc.

Ticker SMMT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 201,215,008
Market Cap $3.97B
Description
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...

More about SMMT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Account